Teva (NYSE: TEVA) EVP Richard Daniell sells 30,000 shares in open-market trade

Rhea-AI Filing Summary

Teva Pharmaceutical Industries EVP Europe Commercial Richard Daniell reported an open-market sale of Teva ordinary shares. On May 5, 2026, he sold 30,000 ordinary shares at $35.40 per share. After this transaction, he directly held 55,755 ordinary shares.

The filing notes that Teva’s ordinary shares may be represented by American Depositary Shares, with each ADS currently corresponding to one ordinary share.

Insider Trade Summary

Net Seller: 30,000 shares ($1,062,000)

Net Sell 1 txn

Insider Daniell Richard

Role EVP, Europe Commercial

Sold 30,000 shs ($1.06M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	30,000	$35.40	$1.06M

Holdings After Transaction: Ordinary Shares — 55,755 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 30,000 shares Sale price: $35.40 per share Shares held after: 55,755 shares +1 more

4 metrics

Shares sold 30,000 shares Open-market sale on May 5, 2026

Sale price $35.40 per share Price for 30,000 ordinary shares sold

Shares held after 55,755 shares Direct ownership following the sale

Security type Ordinary Shares Can be represented by ADS on 1:1 basis

Key Terms

open-market sale, Ordinary Shares, American Depositary Shares

3 terms

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Ordinary Shares financial

"security_title": "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

American Depositary Shares financial

"may be represented by American Depositary Shares, each of which currently"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Daniell Richard

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV ISRAEL 6944020

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Europe Commercial

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares(1)	05/05/2026		S		30,000	D	$35.4	55,755	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

	/s/ Dov Bergwerk as attorney-in-fact for Richard Daniell	05/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did TEVA executive Richard Daniell report?

Richard Daniell reported an open-market sale of Teva ordinary shares. He sold 30,000 shares on May 5, 2026 at a price of $35.40 per share, as disclosed in the Form 4 filing for TEVA.

How many TEVA shares did Richard Daniell retain after the sale?

After the reported sale, Richard Daniell directly held 55,755 Teva ordinary shares. This post-transaction holding is stated in the Form 4 and reflects his remaining direct ownership position following the 30,000-share open-market sale.

At what price were the TEVA shares sold in this Form 4 filing?

The 30,000 Teva ordinary shares were sold at $35.40 per share. This per-share sale price is specified in the Form 4 filing and applies to the entire reported open-market transaction on May 5, 2026.

What role does the reporting person hold at TEVA?

The reporting person, Richard Daniell, serves as Executive Vice President, Europe Commercial at Teva Pharmaceutical Industries. His officer status and title are disclosed in the Form 4, indicating he is a senior executive responsible for Teva’s European commercial operations.

How are TEVA ordinary shares related to American Depositary Shares (ADS)?

The filing explains that Teva’s ordinary shares may be represented by American Depositary Shares. Each ADS currently corresponds to one ordinary share, meaning investors holding ADS effectively have economic exposure equivalent to a single underlying Teva ordinary share.